Management of Non-Alcoholic Fatty Liver Disease (NAFLD)
Lifestyle Modifications and Pharmacologic Interventions
- The American Association for the Study of Liver Diseases recommends lifestyle modifications, including weight loss and exercise, as the cornerstone of therapy for NAFLD, with a target weight loss of 7-10% to improve steatohepatitis and achieve fibrosis regression 1, 2, 4
- A Mediterranean diet with daily vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil is recommended for patients with NAFLD 7, 5, 6
- The American Heart Association recommends at least 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous-intensity exercise weekly for patients with NAFLD 5, 6
- Vitamin E (800 IU/day) improves steatohepatitis in non-diabetic patients with biopsy-proven NASH, though long-term safety concerns exist, according to the American Association for the Study of Liver Diseases 1, 2
- Pioglitazone (30-45 mg/day) benefits select patients with biopsy-proven NASH but causes weight gain and has limited fibrosis improvement data, as stated by the American Diabetes Association 1, 2, 6
Surveillance and Screening
- The American Association for the Study of Liver Diseases recommends hepatocellular carcinoma surveillance every 6 months with ultrasound for patients with advanced fibrosis or cirrhosis, as NASH cirrhosis carries 2-3% annual HCC incidence 3, 5
- Esophagogastroduodenoscopy screening for varices is recommended at diagnosis if cirrhosis is present or if liver stiffness ≥20 kPa, according to the American Gastroenterological Association 3, 5
Management of Metabolic Comorbidities
- Statins are safe and strongly recommended in compensated cirrhosis (Child A-B), reducing hepatic decompensation by 46% and mortality by 46%, as stated by the American College of Cardiology 5, 6
- GLP-1 receptor agonists are preferred for diabetes control given potential liver benefits, according to the American Diabetes Association 5
- Complete alcohol abstinence is mandatory, as even low intake doubles adverse liver outcomes, as recommended by the National Institute on Alcohol Abuse and Alcoholism 6